Amgen, Inc. (AMGN) Holdings Trimmed by Louisiana State Employees Retirement System

Louisiana State Employees Retirement System decreased its holdings in Amgen, Inc. (NASDAQ:AMGN) by 3.7% during the fourth quarter, HoldingsChannel.com reports. The firm owned 43,900 shares of the medical research company’s stock after selling 1,700 shares during the quarter. Louisiana State Employees Retirement System’s holdings in Amgen were worth $7,634,000 at the end of the most recent quarter.

Other hedge funds have also added to or reduced their stakes in the company. FMR LLC grew its position in shares of Amgen by 4.8% during the 2nd quarter. FMR LLC now owns 56,999,572 shares of the medical research company’s stock worth $9,817,037,000 after buying an additional 2,587,041 shares in the last quarter. Vanguard Group Inc. grew its position in shares of Amgen by 0.9% during the 2nd quarter. Vanguard Group Inc. now owns 52,146,935 shares of the medical research company’s stock worth $8,981,266,000 after buying an additional 489,720 shares in the last quarter. BlackRock Inc. grew its position in shares of Amgen by 1.9% during the 2nd quarter. BlackRock Inc. now owns 49,451,203 shares of the medical research company’s stock worth $8,516,980,000 after buying an additional 909,689 shares in the last quarter. Bank of New York Mellon Corp grew its position in shares of Amgen by 1.7% during the 3rd quarter. Bank of New York Mellon Corp now owns 8,166,002 shares of the medical research company’s stock worth $1,522,551,000 after buying an additional 140,117 shares in the last quarter. Finally, Nordea Investment Management AB grew its position in shares of Amgen by 12.9% during the 2nd quarter. Nordea Investment Management AB now owns 7,040,599 shares of the medical research company’s stock worth $1,212,602,000 after buying an additional 806,119 shares in the last quarter. Institutional investors and hedge funds own 78.03% of the company’s stock.

In other Amgen news, EVP Sean E. Harper sold 1,525 shares of the stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $185.62, for a total value of $283,070.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Over the last quarter, insiders sold 4,575 shares of company stock valued at $818,361. 0.19% of the stock is currently owned by company insiders.

AMGN has been the topic of a number of recent research reports. BMO Capital Markets reissued a “market perform” rating and set a $198.00 price target on shares of Amgen in a research report on Thursday, October 26th. BidaskClub raised Amgen from a “strong sell” rating to a “sell” rating in a research report on Saturday, December 2nd. Goldman Sachs Group downgraded Amgen from a “conviction-buy” rating to a “buy” rating in a research report on Friday, December 15th. Zacks Investment Research downgraded Amgen from a “buy” rating to a “hold” rating in a research report on Monday, October 30th. Finally, Piper Jaffray Companies reaffirmed a “buy” rating on shares of Amgen in a research report on Tuesday, January 2nd. Sixteen analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $191.84.

Shares of Amgen, Inc. (NASDAQ:AMGN) opened at $183.55 on Monday. The company has a quick ratio of 5.17, a current ratio of 5.49 and a debt-to-equity ratio of 1.35. Amgen, Inc. has a 12 month low of $152.16 and a 12 month high of $201.23. The company has a market capitalization of $132,259.19, a PE ratio of 14.59, a price-to-earnings-growth ratio of 2.19 and a beta of 1.42.

Amgen (NASDAQ:AMGN) last released its quarterly earnings results on Thursday, February 1st. The medical research company reported $2.89 EPS for the quarter, missing analysts’ consensus estimates of $3.03 by ($0.14). Amgen had a net margin of 8.66% and a return on equity of 30.87%. The business had revenue of $5.80 billion during the quarter, compared to analysts’ expectations of $5.84 billion. During the same quarter last year, the business posted $2.89 earnings per share. The company’s quarterly revenue was down 2.7% compared to the same quarter last year. equities research analysts predict that Amgen, Inc. will post 13.21 EPS for the current year.

Amgen announced that its board has approved a share repurchase plan on Wednesday, October 25th that allows the company to repurchase $5.00 billion in shares. This repurchase authorization allows the medical research company to purchase shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board believes its stock is undervalued.

The firm also recently declared a quarterly dividend, which will be paid on Thursday, March 8th. Shareholders of record on Thursday, February 15th will be paid a $1.32 dividend. The ex-dividend date of this dividend is Wednesday, February 14th. This is a boost from Amgen’s previous quarterly dividend of $1.15. This represents a $5.28 dividend on an annualized basis and a yield of 2.88%. Amgen’s dividend payout ratio (DPR) is 205.45%.

COPYRIGHT VIOLATION WARNING: “Amgen, Inc. (AMGN) Holdings Trimmed by Louisiana State Employees Retirement System” was originally posted by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this report on another domain, it was stolen and republished in violation of US & international copyright and trademark laws. The correct version of this report can be accessed at https://stocknewstimes.com/2018/02/19/amgen-inc-amgn-holdings-trimmed-by-louisiana-state-employees-retirement-system.html.

Amgen Profile

Amgen Inc is a biotechnology company. The Company discovers, develops, manufactures and delivers various human therapeutics. It operates in human therapeutics segment. Its marketed products portfolio includes Neulasta (pegfilgrastim); erythropoiesis-stimulating agents (ESAs), such as Aranesp (darbepoetin alfa) and EPOGEN (epoetin alfa); Sensipar/Mimpara (cinacalcet); XGEVA (denosumab); Prolia (denosumab); NEUPOGEN (filgrastim), and other marketed products, such as KYPROLIS (carfilzomib), Vectibix (panitumumab), Nplate (romiplostim), Repatha (evolocumab), BLINCYTO (blinatumomab), IMLYGIC (talimogene laherparepvec) and Corlanor (ivabradine).

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen, Inc. (NASDAQ:AMGN).

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply